Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q2 FY24 results · Jul–Sep 2023
Natco Pharma reported revenue from operations of ₹1,031.40 crore (up 138.7% from Q2 FY23) and net profit of ₹369.00 crore (up 549.6% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,031.40 | 432.10 | +138.7% | 1,140.50 | −9.6% |
| Other income | 29.40 | 20.50 | +43.4% | 19.70 | +49.2% |
| Total income | 1,060.80 | 452.60 | +134.4% | 1,160.20 | −8.6% |
| Profit before tax | 439.60 | 70.30 | +525.3% | 500.00 | −12.1% |
| Net profit for the period | 369.00 | 56.80 | +549.6% | 420.30 | −12.2% |
| EPS, basic (₹) | 20.60 | 3.11 | +562.4% | 23.26 | −11.4% |
| Net margin (%) | 35.8 | 13.1 | 36.9 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 930.50 | 351.10 | +165.0% | 1,048.30 | −11.2% |
| Other income | 24.70 | 16.20 | +52.5% | 14.60 | +69.2% |
| Total income | 955.20 | 367.30 | +160.1% | 1,062.90 | −10.1% |
| Profit before tax | 424.00 | 46.30 | +815.8% | 475.20 | −10.8% |
| Net profit for the period | 360.20 | 37.70 | +855.4% | 405.30 | −11.1% |
| EPS, basic (₹) | 20.11 | 2.07 | +871.5% | 22.43 | −10.3% |
| Net margin (%) | 38.7 | 10.7 | 38.7 |
Consolidated
- Filed with BSE
- 15 Nov 2023, 17:02 IST
- Board meeting
- 14 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Nov 2023, 17:02 IST
- Board meeting
- 14 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE